Related Experiment Video
Updated: Sep 19, 2025
Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice
Published on: May 4, 2015
An immunostaining-based approach for assessing myocardial viability in the infarcted mouse hearts
Weili Ouyang1, Xueqing Liu1, Zheheng Ding2
1Department of Cardiology, The People's Hospital of Danyang, Affiliated Danyang Hospital of Nantong University, Danyang, China.
Insights
Antibody staining of cardiac troponin I (cTnI) offers a simple method for assessing cardiomyocyte viability after myocardial infarction (MI). This technique precisely detects infarct areas early, even with intact cell membranes.
Area of Science:
- Cardiovascular Biology
- Spatial Biology
- Biomarker Discovery
Background:
- Accurate assessment of cardiomyocyte viability is crucial in spatial biology, especially after myocardial infarction (MI).
- Cardiac troponin I (cTnI) is released abundantly within 24 hours post-MI.
- Early detection of cell death and infarct size is vital for understanding cardiac injury.
Purpose of the Study:
- To introduce and validate antibody-based cardiac troponin I (cTnI) staining as a tool for assessing cardiomyocyte viability.
- To evaluate the utility of cTnI staining for early detection of myocardial infarction (MI) and infarct area delineation.
- To compare cTnI staining with other sarcomeric proteins and imaging techniques for myocardial viability assessment.
Main Methods:
- Utilized antibody-based staining to detect cardiac troponin I (cTnI) in heart sections at various time points post-MI.
- Compared cTnI staining patterns with other sarcomeric proteins (troponin T, α-actinin) and standard infarct staining (TTC).
- Validated findings using in vivo and ex vivo measurements, including manganese-enhanced magnetic resonance imaging (MEMRI).
Main Results:
- Partial depletion of cTnI staining was observed in dying cardiomyocytes as early as 6 hours post-MI, with near absence by 24 hours.
- cTnI staining loss occurred despite preserved membrane integrity, unlike other sarcomeric proteins.
- cTnI staining demonstrated precise cellular-level overlap with TTC staining and highly consistent infarct area detection (r²=0.96) compared to MEMRI.
Conclusions:
- Antibody-based cTnI staining is a valuable and simple tool for early assessment of myocardial viability.
- The technique provides high spatial resolution for detecting infarct areas following ischemic injury.
- cTnI staining highlights the coordinated breakdown of sarcomeric proteins in response to cardiac ischemia.
Introduction:
With the growing need for reliable and precise detection of cell viability in spatial biology, we introduce an antibody-based staining of cardiac troponin I (cTnI) as a simple yet valuable tool for delineating cardiomyocyte viability in the early stages of myocardial infarction (MI).
Methods & Results:
In circulation, cTnI was found to be the most abundantly released biomarker within the first 24 h after MI. In heart sections, partial depletion of cTnI staining was observed within dying cardiomyocytes as early as 6 h, with almost absence by 24 h despite of preserved membrane integrity. In contrast, staining for other sarcomeric proteins, such as troponin T and α-actinin, remained detectable for several days until immune cells infiltration occurred. We further validated the rapid loss of cTnI staining by cross-verifying in-vivo and ex-vivo measurements. Notably, cTnI-stained sections showed precise overlap with TTC-stained images at the cellular level and showed a highly consistent pattern of cardiomyocyte distribution and infarct area (r² = 0.96) when compared to in-vivo measurements using manganese-enhanced magnetic resonance imaging (MEMRI).
Conclusion:
These findings highlight the coordinated, stepwise breakdown of sarcomeric proteins following ischemic injury in the mouse heart and underscore the utility of antibody-based cTnI staining as a valuable tool for early myocardial viability assessment and infarct area detection with high spatial resolution.
